

# NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

## GUIDANCE EXECUTIVE (GE)

### Consideration of consultation responses on review proposal

#### Review of TA34 trastuzumab for the treatment of advanced breast cancer

This guidance was issued in March, 2002. The review date for this guidance was April 2005. At this point it was decided that TA34, TA54 (vinorelbine for the treatment of advanced breast cancer) and TA62 (capecitabine for the treatment of locally advanced or metastatic breast cancer) would be updated as part of clinical guideline CG81 Advanced breast cancer.

During the development of CG81, TA54 and TA62 (along with TA30 taxanes) were updated in the clinical guideline. Despite the original scope for the guideline stating that TA34 would also be updated, the final documents state that TA34 is cross-referenced but not updated in CG81. The guideline recommends that TA34 should be reviewed separately.

#### Background

At the GE meeting on 19 May 2009 it was agreed we would consult on the review plans for this guidance. A four week consultation was conducted with consultees and commentators and the responses are presented below.

<b>Proposal put to consultees:</b>	A review of the guidance should be planned into the appraisal work programme. That we consult on the proposal.
------------------------------------	--

GE is asked to consider the original proposal in the light of the comments received from consultees and commentators, together with any responses from the appraisal team. It is asked to agree on the final course of action for the review.

<b>Recommendation post consultation:</b>	A review of the guidance should be planned into the appraisal work programme
--	--

Respondent	Response to proposal	Details	Comment from Technology Appraisal
Roche Products (trastuzumab)	No objection	"Trastuzumab has since received two additional licences for use in combination with (1) docetaxel and (2) aromatase inhibitors. If NICE wishes to review these indications, we would suggest that	The license for trastuzumab does not consider the combination with docetaxel or aromatase inhibitor and therefore any appraisal considering

		these be reviewed as new STA appraisals.”	these indications should be a new appraisal.
GlaxoSmithKline (lapatinib)	No objection	Submitted details of clinical trials that may be of interest for the proposed review.	Comment noted.
Royal College of Nursing	No objection		Comment noted.
Royal College of Physicians, Medical Oncology Joint Special Committee	Agree		Comment noted.
Royal College of Pathologists	Disagree	Not aware of any evidence that would suggest the need for a review.	Comment noted.
Nottingham City PCT (now known as NHS Nottingham City)	Agree		Comment noted.

**No response received from:**

<b>Consultees</b>	<b>Consultees</b>	<b>Commentators (no right to submit or appeal)</b>
<u>Patient/carer groups</u> <ul style="list-style-type: none"> <li>• Afiya Trust</li> <li>• Age Concern England</li> <li>• Black Health Agency</li> <li>• Breakthrough Breast Cancer</li> <li>• Breast Cancer Campaign</li> <li>• Breast Cancer Care</li> <li>• Breast Cancer Haven</li> <li>• Breast Cancer UK</li> <li>• CANCERactive</li> <li>• Cancerbackup</li> <li>• Cancer Black Care</li> <li>• Cancer Equality</li> <li>• Cancer Voices</li> <li>• Chinese National Healthy Living Centre</li> </ul>	<u>Professional groups</u> <ul style="list-style-type: none"> <li>• Association of Cancer Physicians</li> <li>• British Association for Services to the Elderly</li> <li>• British Geriatrics Society</li> <li>• British Oncological Association</li> <li>• British Psychosocial Oncology Society</li> <li>• Cancer Networks Pharmacists Forum</li> <li>• Cancer Research UK</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Radiologists</li> <li>• Royal Society of Medicine – Intellectual Disabilities Forum</li> <li>• United Kingdom Clinical Pharmacy Association</li> <li>• United Kingdom Oncology Nursing Society</li> </ul>	<ul style="list-style-type: none"> <li>• NHS Purchasing and Supply Agency</li> <li>• NHS Quality Improvement Scotland</li> <li>• Scottish Medicines Consortium</li> </ul> <u>Comparator manufacturers</u> <ul style="list-style-type: none"> <li>• Novartis Pharmaceuticals (letrozole)</li> <li>• Roche Products (capecitabine)</li> </ul> <u>Relevant research groups</u> <ul style="list-style-type: none"> <li>• Against Breast Cancer</li> <li>• Breast Cancer Hope</li> <li>• Breast Cancer Research Trust</li> <li>• Cochrane Collaboration – Cochrane Breast Cancer Group</li> <li>• Institute of Cancer Research</li> </ul>

Consultees	Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> <li>• Confederation of Indian Organisations</li> <li>• Counsel and Care</li> <li>• Equalities National Council</li> <li>• Helen Rollason Heal Cancer Charity</li> <li>• Help the Aged</li> <li>• Macmillan Cancer Support</li> <li>• Maggie’s Centres</li> <li>• Marie Curie Cancer Care</li> <li>• Muslim Council of Great Britain</li> <li>• Muslim Health Network</li> <li>• National Cancer Alliance</li> <li>• National Council for Palliative Care</li> <li>• Specialised Healthcare Alliance</li> <li>• South Asian Health Foundation</li> <li>• Sue Ryder Care</li> <li>• Tenovus Cancer Information Centre</li> <li>• Women’s Health Concern</li> </ul>	<p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Anglesey LHB</li> <li>• Department of Health</li> <li>• Welsh Assembly Government</li> </ul> <p><b>Commentators (no right to submit or appeal)</b></p> <p><u>General</u></p> <ul style="list-style-type: none"> <li>• Age Concern Cymru</li> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Cancer Care Cymru</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Medicines and Healthcare products Regulatory Agency</li> <li>• National Association for Primary Care</li> <li>• National Public Health Service for Wales</li> <li>• NHS Alliance</li> <li>• NHS Confederation</li> </ul>	<ul style="list-style-type: none"> <li>• MRC Clinical Trials Unit</li> <li>• National Cancer Research Institute</li> <li>• National Cancer Research Network</li> <li>• National Institute for Health Research</li> <li>• Policy Research Institute on Ageing and Ethnicity</li> <li>• Pro-Cancer Research Fund</li> <li>• Radiological Research Trust</li> <li>• Research Institute for the Care of Older People</li> </ul> <p><u>Assessment Group</u></p> <ul style="list-style-type: none"> <li>• Assessment Group tbc</li> <li>• National Institute for Health Research Health Technology Assessment Programme</li> </ul> <p><u>Associated Guideline Groups</u></p> <ul style="list-style-type: none"> <li>• National Collaborating Centre for Cancer</li> </ul>

**GE paper sign-off:**

Nina Pinwill, Associate Director, CHTE  
16 July 2009

**Contributors to this paper:**

Information Specialist: Daniel Tuvey  
Technical Lead: Andres Roman  
Technical Adviser: Jo Richardson  
Project Manager: Natalie Bemrose